185 related articles for article (PubMed ID: 1420747)
1. Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis.
Morrison G; Morrison JM; Redmond AO; Byers CA; McCracken KJ; Dodge JA; Guilford SA; Bowden MW
Aliment Pharmacol Ther; 1992 Oct; 6(5):549-55. PubMed ID: 1420747
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
[TBL] [Abstract][Full Text] [Related]
3. A comparison of two pancreatin microsphere preparations in cystic fibrosis.
Elliott RB; Escobar LC; Lees HR; Akroyd RM; Reilly HC
N Z Med J; 1992 Mar; 105(930):107-8. PubMed ID: 1553114
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Gan KH; Heijerman HG; Geus WP; Bakker W; Lamers CB
Aliment Pharmacol Ther; 1994 Dec; 8(6):603-7. PubMed ID: 7696449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis.
Mischler EH; Parrell S; Farrell PM; Odell GB
Am J Dis Child; 1982 Dec; 136(12):1060-3. PubMed ID: 7148760
[TBL] [Abstract][Full Text] [Related]
6. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.
Dutta SK; Hubbard VS; Appler M
Dig Dis Sci; 1988 Oct; 33(10):1237-44. PubMed ID: 3168696
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
Santini B; Antonelli M; Battistini A; Bertasi S; Collura M; Esposito I; Di Febbraro L; Ferrari R; Ferrero L; Iapichino L; Lucidi V; Manca A; Pisconti CL; Pisi G; Raia V; Romano L; Rosati P; Grazioli I; Melzi G
Dig Liver Dis; 2000; 32(5):406-11. PubMed ID: 11030186
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Graff GR; McNamara J; Royall J; Caras S; Forssmann K
Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of 2 pancreatic enzyme preparations in the treatment of digestive insufficiency in mucoviscidosis (cystic fibrosis)].
Gottschalk B; Wiesemann HG; Stephan U
Monatsschr Kinderheilkd; 1988 Sep; 136(9):626-9. PubMed ID: 3237230
[TBL] [Abstract][Full Text] [Related]
10. Controversies in the treatment of exocrine pancreatic insufficiency.
DiMagno EP
Dig Dis Sci; 1982 Jun; 27(6):481-4. PubMed ID: 6919479
[No Abstract] [Full Text] [Related]
11. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations.
Kraisinger M; Hochhaus G; Stecenko A; Bowser E; Hendeles L
J Clin Pharmacol; 1994 Feb; 34(2):158-66. PubMed ID: 8163716
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].
Zsíros J; Sólyom E
Orv Hetil; 1988 May; 129(19):995-9. PubMed ID: 3290773
[No Abstract] [Full Text] [Related]
14. [Clinical trial of several preparation types of the pancreatic extract Pancrex V in the treatment of cystic fibrosis].
Braggion C; Mastella G
Minerva Pediatr; 1985 Nov; 37(21-22):891-6. PubMed ID: 3912659
[No Abstract] [Full Text] [Related]
15. Nutritional management and pancreatic enzyme therapy in cystic fibrosis patients: state of the art in 1987 and projections into the future.
George DE; Mangos JA
J Pediatr Gastroenterol Nutr; 1988; 7 Suppl 1():S49-57. PubMed ID: 3042940
[No Abstract] [Full Text] [Related]
16. Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency.
Brugge WR; Goldberg HJ; Burke CA; Depping BJ
Dig Dis Sci; 1988 Oct; 33(10):1226-32. PubMed ID: 3168695
[TBL] [Abstract][Full Text] [Related]
17. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis.
Durie PR; Bell L; Linton W; Corey ML; Forstner GG
Gut; 1980 Sep; 21(9):778-86. PubMed ID: 7429342
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency.
Dutta SK; Rubin J; Harvey J
Gastroenterology; 1983 Mar; 84(3):476-82. PubMed ID: 6549746
[TBL] [Abstract][Full Text] [Related]
19. Duodenal instillation of pancreatin does not abolish steatorrhea in patients with pancreatic insufficiency.
Zerega J; Lerner S; Meyer JH
Dig Dis Sci; 1988 Oct; 33(10):1245-9. PubMed ID: 3168697
[TBL] [Abstract][Full Text] [Related]
20. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
